Novavax, Inc. (NVAX) Stock

Understand Novavax, Inc.: how it makes money

Novavax develops and commercializes vaccines for infectious diseases, and it makes money primarily through vaccine and platform-related partner agreements (for example Sanofi upfront payment recognition and related transition and licensing/royalties revenue), alongside smaller product sales and government grant revenue.

Novavax’s revenue mix is structurally driven by partner agreement economics, including Sanofi-related upfront payment revenue recognition and transition services allocation, then supported by licensing and royalties, rather than by a large scale of recurring product sales in the latest quarter.

Business quality (Solid): The data provided emphasizes partner-agreement revenue categories and a small set of operating KPIs tied to product/dose delivery, and the latest quarter shows high gross margin (78.0%) alongside a negative operating margin (-11.1%), which suggests cost structure and timing matter as much as gross profitability.

Bull case

• Partner agreement revenue provides near-term visibility: The latest quarter includes Sanofi upfront payment revenue recognition (0.39B) and additional allocation over a transition services period (0.12B), plus licensing and royalties revenue (0.1B).
• Some delivery pipeline is already committed: The company reports remaining committed doses for the delivery schedule of 23,000,000.
• Vaccine development is actively progressing in late-stage programs: NVX-CoV2373 is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial, and NanoFlu is in a Phase 3 clinical trial.

Bear case

• Profitability in the latest quarter is negative at the operating level: Operating margin is -11.1% for the quarter ended 2026-03-31.
• Product sales and dose activity are small versus partner economics in the data provided: Nuvaxovid Product Sales are 0.01B, with doses delivered under a modified agreement in the United States reported as 1,500,000 and vaccinated doses sold (commercial product sales) reported as 3,000,000.
• Revenue may be sensitive to the timing and continuation of partner payments: The revenue categories highlighted include Sanofi upfront payment recognition and transition allocation, so changes in partner agreement economics or timing can affect revenue.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Maze Therapeutics, Inc. (MAZE)
• Vir Biotechnology, Inc. (VIR)
• Inhibrx Biosciences, Inc. (INBX)
• MeiraGTx Holdings plc (MGTX)
• Cullinan Therapeutics, Inc. (CGEM)
• Replimune Group, Inc. (REPL)
• Monte Rosa Therapeutics, Inc. (GLUE)
• Vor Biopharma Inc. (VOR)